Go to Site Home Page Go to University of Pittsburgh Home Page Go to UPMC Home Page

Research Areas


Anesthesia Mechanisms

Nausea and Vomiting Mechanisms

Neuronal Injury and Protection

Pain Mechanisms

Patient Safety


Clinical Trials Program
The Department of Anesthesiology maintains its own industry-sponsored Clinical Trials Program (CTP) with Jonathan H. Waters, MD, Vice Chair of Clinical Research, as Program Director.  This program is designed to provide, all the services necessary for faculty members within the department, as both principal investigators and sub-investigators, to start and follow through with a clinical trial.




Barbara Brandom, MD

At present I am the Director of the North American MH Registry (NAMHR), now located at UPMC Mercy Hospital.  With help from the Malignant Hyperthermia (MH) Association of the United States, we continue to collect data from MH susceptible people and their families and health care providers.  As a result, genetic testing for MH susceptibility is performed at UPMC by sequencing 19 exons of the ryanodine receptor type one gene. We encourage researchers across the spectrum to use the NAMHR to investigate MH.  The NAMHR is being used to study the clinical presentation of MH in the operating room and chronic muscular symptoms in MH susceptible people.

E-mail Dr. Brandom

Tomas Drabek, MD

My research carried out at the Safar Center for Resuscitation Research is focused on hemorrhagic shock and resuscitation from both traumatic and non-traumatic cardiac arrest (CA). The main focus is exsanguination CA (ExCA), a relatively unexplored form of CA. Resuscitation of ExCA victims with the conventional cardiopulmonary resuscitation (CPR) technique has a poor prognosis because of a volume-depleted and trauma-disrupted circulatory system. However, in an appropriate setting, many of those injuries would be repairable. We have developed a breakthrough concept of emergency preservation and resuscitation (EPR) that uses cold aortic flush to induce deep hypothermia, thus decreasing metabolic demands to preserve the organs, and buying time for transport and damage-control surgery. Delayed resuscitation is then achieved via cardiopulmonary bypass (CPB). We developed a rat EPR model to elucidate mechanisms associated with ischemia-reperfusion injury, and to test novel therapies. Extended CA durations showed significant regional and temporal differences in neuronal death and neuroinflammation.

Our current work is focused on neuroinflammation-induced reperfusion injury and blocking the deleterious pathways with novel gene-based therapies. We collaborate with the Pittsburgh NMR Center for Biomedical Research at Carnegie Mellon University where cerebral blood flow is assessed with MRI. The use of a rat CPB model also has direct relevance to cardiac anesthesia, including deep hypothermic circulatory arrest.

E-mail Dr. Drabek

Michael Gold, PhD

Pain continues to be a major health problem with tremendous financial, social and psychological costs. Conservative estimates put the cost of pain to the US economy well into the hundreds of billions of dollars per year as a result of associated medical expenses and lost wages with a significant minority of Americans suffering from persistent or recurrent pain syndromes throughout the most productive years of their lives. Just one pain syndrome, migraine headache, directly impacts 20% of the adult population. Yet, there remain few if any effective therapies devoid of serious side effects that are currently available to treat pain, particularly persistent or recurrent pain associated with syndromes.

The clinical features of a number of pain syndromes serve as the organizing focus of research in the Gold laboratory. These observations include the following: 1) many pain syndromes are unique to a particular part of the body such as the head in migraine, the temporomandibular joint in temporomandibular disorder (TMD), or the colon in inflammatory bowel disease (IBD); 2) many pain syndromes such as migraine, TMD and IBD occur with a greater prevalence, severity and/or duration in women than in men; 3) many pain syndromes are associated with changes in the excitability of primary afferent neurons; 4) there are time dependent changes in the mechanisms underlying pain syndromes; and 5) the type of injury, (i.e., inflammation or nerve injury), are differentially sensitive to therapeutic interventions. These observations led to specific hypotheses that are tested in ongoing studies in the Gold laboratory. These include 1) characterizing the mechanisms underlying inflammation-induced changes in the evoked Ca2+ transients in sensory neurons, 2) characterizing the link between sex, stress and the immune system in the context of migraine and visceral pain, 3) characterizing the influence of sex, stress and the immune system on the excitability of spinal and trigeminal ganglion neurons, 4) characterizing the role of changes in inhibitory receptors, in particular GABA, in persistent visceral pain, and 5) identification of ways to maximize the therapeutic utility of local anesthetics. The ultimate goal of these studies is to identify novel targets for the development of therapeutic interventions for the treatment of pain.

E-mail Dr. Gold

Charles Horn, PhD

Dr. Horn’s primary research focus is the neurobiology of vagus nerve signaling in health and disease; and, more generally, the role of gut-brain communication in homeostasis. Numerous medical treatments and diseases affect gut-brain interactions to elicit nausea and emesis, reduce food intake, induce inflammatory responses, and modulate pain; the laboratory conducts studies on the impact of cytotoxic chemotherapy agents, surgical drugs (anesthesia and analgesics), and chronic conditions (e.g., cancer) on these responses. This line of research has the long-term goal of developing treatments to decrease symptom burden and improve quality of life for patients.

E-mail Dr. Horn

Gregg Homanics, PhD

My research interests are focused on the mechanism(s) of action of alcohol and anesthetics.  My lab is attempting to gain mechanistic insight into the processes of alcohol intoxication and general anesthesia by creating and analyzing genetically altered mice. Specifically, experiments are in progress to genetically dissect the GABA neurotransmitter pathway. GABA receptor knockout, knockin, and overexpressing mice are also helping to elucidate mechanisms of epilepsy, learning and memory, behavior, drug action, and developmental abnormalities as well as serving as models of human genetic disorders, e.g., Angelman Syndrome and essential tremor.

E-mail Dr. Homanics

James W. Ibinson, MD, PhD

The chief focus of my research is the functional magnetic resonance imaging (FMRI) of pain processing. Currently, we are expanding the knowledge of how longer stimulations are processed and investigating the changes in brain activation that accompany long-duration painful stimulation, illustrating those areas of the brain that experience the greatest signal changes due to accommodation. In addition, projects are in place to research the connection between genetics and brain activation, as well as exploring the impact that treatment of neuropathic pain can have on the brain's activation pattern. As a practicing anesthesiologist, I believe that the role of the physician-scientist is to translate the tools, techniques, and treatments derived in the basic science laboratories to the clinical realm. Thus, the overall goal of these three projects is to further our understanding of chronic pain and impact future treatment strategies and success.

E-mail Dr. Ibinson

Eric Kelley, PhD

Dr. Kelley’s research centers on the role of oxidative stress in vasculature inflammation with a primary focus on the modulation of endothelial homeostasis by xanthine oxidase (XO)-derived ROS. Such ROS production, when it occurs in the vascular compartment, can impact vessel function by modulation of redox-dependent cell signaling reactions or by the reduction of •NO bioavailability due to its direct reaction with superoxide. An expanding number of animal models and clinical studies affirm a key role for XO in tissue pathology where inhibition of XO activity attenuates symptoms of vascular disease. However, recently reported studies demonstrate under severe hypoxia, XO may function as a nitrite reductase and thus assume a protective role by serving as a source of vasoactive nitric oxide (NO). Therefore, in order to develop novel treatment strategies, Dr. Kelley’s efforts are globally targeted to develop a more comprehensive understanding of XO-derived ROS/RNS in vascular inflammatory processes.

E-mail Dr. Kelley

William McIvor, MD

I am interested in developing and implementing simulation education for medical students, resident-physicians and practicing physicians. Methods and impact of the education are of particular interest.

E-mail Dr. McIvor

Tetsuro Sakai, MD, PhD

Dr. Sakai’s current research interests span several areas. As director of the resident research rotation, he focuses on resident research education and has built up a system to facilitate resident scholarly participation and productivity. As a member of the transplant anesthesiology team, he is interested in improving intraoperative management of liver/small bowel/multivisceral transplant patients. Dr. Sakai is also interested in system-based practice management, using quality improvement information in a simulation center setting to improve patient safety.

E-mail Dr. Sakai

Pei Tang, PhD

My research focuses on the molecular mechanisms of general anesthesia. Using a hydrate biophysical approach, we have been working on two major projects. The first one is to determine high-resolution structures of neurotransmitter-gated receptor channels, such as neuronal nicotinic acetylcholine receptors. These receptors are not only the targets for general anesthetics, but also for CNS therapeutics. Since the current structural information of these receptors is still very limited, our research will provide valuable structural bases for searching for drug binding sites. The second project aims to understand how low affinity drugs, including inhaled and intravenous general anesthetics, modulate protein motions that ultimately have impact on protein functions. Through our experiments and computations, we are testing our new hypothesis: the lock and key relationship does not accurately describe the action of low affinity drugs on proteins, the modulation on protein motions is the mechanistic underpinnings of action of general anesthetics and other low affinity drugs.

E-mail Dr. Tang                  |              Visit Dr. Tang's Lab

Brian Williams, MD, MBA

I have been pursuing translational bench-to-bedside research since 2007, now with clinical trial funding from the Department of Defense, developing multimodal single-injection perineural anesthesia/analgesia (i.e., “nerve block”). Our specific goals include maximizing the duration of sensory analgesia while minimizing the duration of motor and proprioceptive block. The public health objectives are to render single-injection nerve block techniques both more efficacious for patients and more accessible for anesthesiologists to administer quickly. My past research interests included the restructuring of anesthesia care processes to render regional anesthesia as the primary anesthetic technique (spinal, single-injection peripheral nerve block, continuous nerve block), while relegating general endotracheal anesthesia to the "backup" plan. My work has addressed health care economics and hospital staff workload (in retrospective study), as well as patient-reported outcomes via validated survey instruments (in prospective study).

E-mail Dr. Williams

Yan Xu, PhD

Current research efforts are directed at combining new innovations in powerful gene therapy and stem-cell therapy with state-of-the-art MRI techniques. Our laboratory has developed a clinically relevant cardiac arrest and resuscitation model that is fully compatible with noninvasive magnetic resonance spectroscopy and imaging techniques, thus permitting pharmacological intervention and long-term outcome to be investigated.  New gene therapy strategies are being developed to target a special event called reperfusion injury after cardiac arrest and resuscitation. Recently, our group has combined gene therapy with stem cell therapy using a non-controversial source of stem cells, in an effort to stop and reverse neuronal loss and to rebuild neuronal circuitry after reperfusion from prolonged cardiac arrest or stroke.

Our group is one of the leading groups in the world to combine the high-resolution and solid-state NMR techniques to solve membrane protein structures at the atomic resolution.  The current focus is on the transmembrane domain structures of the human glycine receptor (GlyR), the primary inhibitory receptor in the spinal cord and the brain stem which is responsible for a wide range of neurological diseases including the startle disease (hyperekplexia), epilepsy, and Parkinson's disease.  The long-term goal is to provide the structural basis for novel design of drugs that are disease specific and devoid of side effects.

We are also studying low-affinity drug interaction with membrane proteins.  Experimental and theoretical approaches are combined to study how low affinity neurological agents, such as alcohol and general anesthetics exert their effects on the central nervous system at the molecular level. The goal is to shed new light on the great unsolved mystery of modern medicine: the molecular mechanisms of general anesthesia.

E-mail Dr. Xu                    |             Visit Dr. Xu's Lab

Charles Yang, MD

E-mail Dr. Yang

Li-Ming Zhang, MD

It is well known that mechanical ventilation may produce an iatrogenic condition referred to as ventilator-induced lung injury (VILI). VILI can contribute to mortality in patients with acute lung injury (ALI). Patients vary greatly in VILI sensitivity suggesting that genetic determinants may control individual susceptibility. Our research lab is currently focusing on functional genomics of ventilator-induced lung injury. We adopted a Genome-wide association study (GWAS) technique to interrogate the entire genome simultaneously to detect loci linked to a phenotype that reside in previously unsuspected genes and/or regions in 40 inbred strains of mice exposed to VILI induced by high tidal volume ventilation. Our initial GWAS analysis identified 18 genes with significant SNP linkage [–log (P) = 6.0 to 9.5]. Of these, 4 genes (Adcy8, Asap1, Ndrg1 and Wisp1) were located in a single region (64.1 – 66.7 Mbp) on chromosome 15. Our goals are to identify these target candidate genes by pulmonary functional assessment and provide novel insights into the underlying pathogenesis of VILI and ultimately help translate animal studies to patient care to minimize the detrimental effects of using mechanical ventilation in human subjects and to guide novel therapeutic interventions to ALI.

E-mail Dr. Zhang